PHILADELPHIA—Mirabegron is a safe and effective treatment for overactive bladder (OAB) in older patients, a researcher reported at the International Continence Society’s 2018 annual meeting.

Adrian Wagg, MB, BS, of the University of Alberta in Edmonton, presented findings from a 12-week phase 4 prospective, randomized, placebo-controlled trial that enrolled 888 patients older than 65 years who had OAB symptoms for 3 months or more. The mean age of the patients was about 72 years. The proportion of patients older than 75 years was 28% among mirabegron and placebo recipients.

Investigators randomly 445 patients to receive mirabegron and 443 to receive placebo. Among the mirabegron patients, 226 received 25 mg and 219 opted to titrate to mirabegron 50 mg by the end of the study. From baseline to end of treatment, mirabegron-treated patients experienced significantly greater declines in the mean number of incontinence episodes per 24 hours (˗2.06 vs ˗1.57) and mean number of micturitions per 24 hours (˗2.5 vs ˗2.0) compared with placebo recipients, based on 3-day micturition diaries.